Company Overview and News

CEI: Camber Energy Analysis and Research Report

2018-05-14 - Asif

Overview Camber Energy, Inc., a Nevada corporation, is an independent oil and natural gas company based in San Antonio, Texas. Camber Energy is engaged in the acquisition, development and sale of crude oil, natural gas and natural gas liquids from various known productive geological formations, including from the Hunton formation in Lincoln, Logan and Payne Counties, in central Oklahoma; the Cline shale and upper Wolfberry shale in Glasscock County, Texas; and recently in connection with its entry into the Horizontal San Andres play on the Central Basin Platform of the Permian Basin in West Texas announced on January 3, 2017. Incorporated in Nevada in December 2003 under the name Panorama Investments Corp., the Company changed its name to Lucas Energy, Inc. effective June 9, 2006 and effective January 4, 2017, the Company changed its name to Camber Energy, Inc. The company's primary value drivers are its reserves which must be developed to unlock their full potential. The company...

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to PSE:CEI / Crown Equities, Inc. on message board site Silicon Investor.

Ask and You Shall Receive Ask and You Shall Receive Ask and You Shall Receive OncoSec (ONCS) Receives ISO 13485 Quality Management System OncoSec (ONCS) Receives ISO 13485 Quality Management System OncoSec (ONCS) Receives ISO 13485 Quality Management System
OncoSec (ONCS) Receives ISO 13485 Quality Management System OncoSec (ONCS) Receives ISO 13485 Quality Management System OncoSec (ONCS) Receives ISO 13485 Quality Management System Banco Itau Holding Financeira S.A. (ITU) Banco Itau Holding Financeira S.A. (ITU) Banco Itau Holding Financeira S.A. (ITU)
BILL CLINTON - DEMOCRAT, LIAR AND DECEIVER BILL CLINTON - DEMOCRAT, LIAR AND DECEIVER BILL CLINTON - DEMOCRAT, LIAR AND DECEIVER ACEI: American Champion Enter. ACEI: American Champion Enter. ACEI: American Champion Enter.
Crescent Real Estate Eq (CEI) Crescent Real Estate Eq (CEI) Crescent Real Estate Eq (CEI) IAH - Internet archetecture Depository Receipts IAH - Internet archetecture Depository Receipts IAH - Internet archetecture Depository Receipts
BHH -- the B2B Depository Receipts BHH -- the B2B Depository Receipts BHH -- the B2B Depository Receipts CANADIAN CLOSED END FUNDS AND INSTALLMENT RECEIPTS CANADIAN CLOSED END FUNDS AND INSTALLMENT RECEIPTS CANADIAN CLOSED END FUNDS AND INSTALLMENT RECEIPTS